HYTN Enables Global Market Access For Non-Sterile Pharmaceuticals
We are revolutionizing the delivery of natural medicines to patients worldwide.
HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. Our mission is to become the leading provider of these products in federally regulated markets worldwide. We achieve this by identifying emerging opportunities and leveraging our advanced development platform to rapidly introduce innovative products to market.
Global Reach
Internationally, HYTN serves as a pharmaceutical manufacturer and processor, transforming Canadian-grown cannabis flower into GMP-certified medicines for distribution in markets such as Australia, the United Kingdom, and Germany. We collaborate with Canadian cannabis producers to extend their reach to global clients and work with international distributors and pharmaceutical companies to develop and supply products tailored to their markets.
Canadian Operations
In Canada, HYTN manufactures, markets, and distributes a line of cannabis-infused beverages and Nano-Shots under the HYTN brand, powered by our proprietary Elevation Technology. Our products are available in major markets, including Ontario, Quebec, Alberta, British Columbia, Nova Scotia, Manitoba, Yukon, and the Northwest Territories, and are carried by most national cannabis retailers.
Other Projects
HYTN is also equipped to manufacture GMP-certified products from other restricted input materials, such as psilocybin-containing mushrooms, for both domestic and international markets. We partner with brands aiming to launch their products globally and work with international distributors to supply medicines containing restricted materials for special access programs, clinical trials, or prescriber use.